MannKind (MNKD) investor relations material

Executive summary

• Achieved three major growth catalysts: Afrezza pediatric launch, FDA approval of FUROSCIX ReadyFlow autoinjector, and positive Phase 1b nintedanib DPI results in IPF patients.

• Q2 2026 total revenues reached $109.4M, up 43% year-over-year, driven by new product launches and portfolio expansion.

• Diversification strategy succeeded as marketed products overtook royalties as the top revenue source for the first time.

• Afrezza pediatric launch off to a strong start, with significant early adoption and broad prescriber engagement.

• FUROSCIX ReadyFlow launch imminent, expected to drive further growth and margin improvement.

Financial highlights

• Q2 2026 revenue reached $109.4M, up 43% year-over-year; first half revenue $199.5M, up 29%.

• FUROSCIX net sales $22.2M, up 43% sequentially; Afrezza net sales $17.0M.

• Royalty revenue $32.4M (+4% YoY); collaboration/services revenue $35M (+53% YoY).

• GAAP net loss of $19M (vs. $0.7M net income prior year); non-GAAP net loss $2.7M (vs. $13.9M net income prior year), reflecting investment in launches and development.

• Operating expenses increased 54% YoY in Q2, with SG&A up 84% and R&D up 32% due to portfolio expansion and new product launches.

Outlook and guidance

• FUROSCIX guidance of $110M–$120M for 2026 reaffirmed; expects back-half weighted sales due to payer dynamics and product transition.

• ReadyFlow launch expected to accelerate growth and improve gross margins in 2027.

• Afrezza pediatric program expected to drive continued momentum, with new dose forms targeted for 2027.

• Continued advancement of nintedanib DPI into Phase 2 for IPF; ralinepag DPI IND filing on track for year-end 2026.

• Focus shifting from launch preparation to disciplined execution and investment prioritization.